ClC-3の阻害は,Akt/ mTOR経路経由でシスプラチン抵抗を逆転させるため,オートファギーを誘導する.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。クロライドチャネル-3 (ClC-3) をターゲットにすることで,子宮頸がんにおけるシスプラチン化学療法の効果が向上します. ClC-3を阻害すると,オートファギーを調節することで化学抵抗性が低下し,患者にとって新しい治療戦略が提供されます.
科学分野
- 腫瘍学
- 分子生物学
- ガン治療薬
背景
- 子宮頸がんは 女性にとって 世界的に大きな健康問題です
- シスプラチンは主要な非手術療法ですが,化学抵抗性が有効性を制限しています.
- クロライドチャネル-3 (ClC-3) 発現は子宮頸がんにおいて上昇し,オートファギーによる化学抵抗と関連している.
研究 の 目的
- 子宮頸がんにおけるClC-3の自己消化とシスプラチン感受性の関係を調査する.
- シスプラチン耐性を克服するための潜在的な治療標的としてClC-3を調査する.
主な方法
- 子宮頸がん細胞系におけるClC-3発現の抑制 (SiHaとSiHa/DDP)
- シスプラチンの感受性および自調節の評価
- ClC-3阻害剤 (CLTX) とシスプラチンで治療された子宮頸がんの異種移植を用いたin vivo試験.
主要な成果
- ClC-3を阻害すると,SiHa細胞におけるシスプラチンに対する感受性が著しく増加した.
- ClC-3の抑制により,SiHa/ DDP細胞系におけるシスプラチン耐性が逆転した.
- Akt- mTOR経路は,ClC-3誘発の自己消化作用を媒介し,化学抵抗に影響を与えた.
- クロロロトキシンTFA (CLTX) はシスプラチン in vivo の有効性を改善しました.
結論
- ClC-3は,子宮頸がんにおけるオートファジー誘発の化学抵抗を媒介する上で重要な役割を果たします.
- CLTXのような阻害剤でClC-3を標的にすると,子宮頸がんがシスプラチンに敏感になる可能性があります.
- この研究は,子宮頸がんの治療を改善するためのメカニズム的な理解と潜在的な治療戦略を提供します.
関連する概念動画
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...